{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:14:30Z","timestamp":1792124070079,"version":"4.4.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Vet Res"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12917-018-1566-1","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T13:16:10Z","timestamp":1534511770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Six-month safety evaluation of robenacoxib tablets (Onsior\u2122) in dogs after daily oral administrations"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6341-7626","authenticated-orcid":false,"given":"C\u00e9line E.","family":"Toutain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Brossard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen B.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Helbig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"issue":"2","key":"1566_CR1","doi-asserted-by":"publisher","first-page":"89","DOI":"10.3844\/ajavsp.2013.89.97","volume":"8","author":"TW Kim","year":"2013","unstructured":"Kim TW, Giorgi M. A brief overview of the coxib drugs in the veterinary field. Am J Anim Vet Sci. 2013;8(2):89\u201397.","journal-title":"Am J Anim Vet Sci"},{"key":"1566_CR2","volume-title":"Onsior: European Public Assessment Report, Scientific discussion","author":"European Medicines Agency","year":"2008","unstructured":"European Medicines Agency. Onsior: European Public Assessment Report, Scientific discussion. 2008. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Scientific_Discussion\/veterinary\/000127\/WC500067756.pdf . Accessed 06 Mar 2018."},{"issue":"1","key":"1566_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2885.2008.00962.x","volume":"32","author":"JN King","year":"2009","unstructured":"King JN, Dawson J, Esser RE, Fujimoto R, Kimble EF, Maniara W, et al. Preclinical pharmacology of robenacoxib: a novel selective inhibitor of cyclooxygenase-2. J Vet Pharmacol Ther. 2009;32(1):1\u201317.","journal-title":"J Vet Pharmacol Ther"},{"issue":"3","key":"1566_CR4","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/j.rvsc.2009.11.002","volume":"88","author":"JN King","year":"2010","unstructured":"King JN, Rudaz C, Borer L, Jung M, Seewald W, Lees P. In vitro and ex vivo inhibition of canine cyclooxygenase isoforms by robenacoxib: a comparative study. Res Vet Sci. 2010;88(3):497\u2013506.","journal-title":"Res Vet Sci"},{"issue":"1","key":"1566_CR5","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/j.1365-2885.2008.01031.x","volume":"32","author":"JM Giraudel","year":"2009","unstructured":"Giraudel JM, Toutain PL, King JN, Lees P. Differential inhibition of cyclooxygenase isoenzymes in the cat by the NSAID robenacoxib. J Vet Pharmacol Ther. 2009;32(1):31\u201340.","journal-title":"J Vet Pharmacol Ther"},{"issue":"1","key":"1566_CR6","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/j.1365-2885.2008.01016.x","volume":"32","author":"JM Giraudel","year":"2009","unstructured":"Giraudel JM, King JN, Jeunesse EC, Lees P, Toutain PL. Use of a pharmacokinetic\/pharmacodynamic approach in the cat to determine a dosage regimen for the COX-2 selective drug robenacoxib. J Vet Pharmacol Ther. 2009;32(1):18\u201330.","journal-title":"J Vet Pharmacol Ther"},{"issue":"2","key":"1566_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/j.1365-2885.2009.01117.x","volume":"33","author":"VB Schmid","year":"2010","unstructured":"Schmid VB, Spreng DE, Seewald W, Jung M, Lees P, King JN. Analgesic and anti-inflammatory actions of robenacoxib in acute joint inflammation in dog. J Vet Pharmacol Ther. 2010;33(2):118\u201331.","journal-title":"J Vet Pharmacol Ther"},{"issue":"3","key":"1566_CR8","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1365-2885.2010.01209.x","volume":"34","author":"JN King","year":"2011","unstructured":"King JN, Arnaud JP, Goldenthal EI, Gruet P, Jung M, Seewald W, et al. Robenacoxib in the dog: target species safety in relation to extent and duration of inhibition of COX-1 and COX-2. J Vet Pharmacol Ther. 2011;34(3):298\u2013311.","journal-title":"J Vet Pharmacol Ther"},{"issue":"3","key":"1566_CR9","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/j.1365-2885.2011.01320.x","volume":"35","author":"JN King","year":"2012","unstructured":"King JN, Hotz R, Reagan EL, Roth DR, Seewald W, Lees P. Safety of oral robenacoxib in the cat. J Vet Pharmacol Ther. 2012;35(3):290\u2013300.","journal-title":"J Vet Pharmacol Ther"},{"issue":"5","key":"1566_CR10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1111\/jvim.12127","volume":"27","author":"BP Monteiro-Steagall","year":"2013","unstructured":"Monteiro-Steagall BP, Steagall PV, Lascelles BD. Systematic review of nonsteroidal anti-inflammatory drug-induced adverse effects in dogs. J Vet Intern Med. 2013;27(5):1011\u20139.","journal-title":"J Vet Intern Med"},{"key":"1566_CR11","volume-title":"European Public Assessment Report, Onsior Summary of Product Characteristics","author":"European Medicines Agency","year":"2008","unstructured":"European Medicines Agency. European Public Assessment Report, Onsior Summary of Product Characteristics. 2008. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/veterinary\/000127\/WC500067759.pdf . . Accessed 06 Mar 2018."},{"key":"1566_CR12","unstructured":"Food and Drug Administration Freedom of Information Summary: Original New Animal Drug Application NADA 141\u2013463 (Onsior Robenacoxib Tablets Dogs). 2016. https:\/\/www.regulations.gov\/document?D=FDA-2016-N-0002-0026 . Accessed 14 Aug 2018."},{"key":"1566_CR13","unstructured":"Veterinary International Conference on Harmonization (VICH) Guideline 43: Target Animal Safety for Veterinary Pharmaceutical Products. 2008. http:\/\/www.vichsec.org\/guidelines\/pharmaceuticals\/pharma-safety\/pharma-target-animal-safety.html . Accessed 06 Mar 2018."},{"key":"1566_CR14","unstructured":"United States Food and Drug Administration, Code of Federal Regulations Title 21, Part 58, Good Laboratory Practice for nonclinical laboratory studies. https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfcfr\/CFRSearch.cfm? CFRPart=58. Accessed 06 Mar 2018."},{"key":"1566_CR15","unstructured":"Organisation for Economic Cooperation and Development (OECD) Series on Principles of Good Laboratory Practice (GLP) and Compliance Monitoring. http:\/\/www.oecd.org\/chemicalsafety\/testing\/oecdseriesonprinciplesofgoodlaboratorypracticeglpandcompliancemonitoring.htm . Accessed 06 Mar 2018."},{"key":"1566_CR16","unstructured":"U.S. Department of Agriculture\u2019s Animal Welfare Act, 9 CFR Parts 1, 2 and 3. 1989. https:\/\/www.federalregister.gov\/topics\/animal-welfare . Accessed 06 Mar 2018."},{"key":"1566_CR17","volume-title":"Institute of Laboratory Animal Resources","author":"Guide for the Care and Use of Laboratory Animals","year":"1996","unstructured":"Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources. Washington, D.C: National Academy Press; 1996."},{"issue":"4","key":"1566_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.joca.2012.02.010","volume":"20","author":"C Kilkenny","year":"2012","unstructured":"Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. Osteoarthr Cartil. 2012;20(4):256\u201360.","journal-title":"Osteoarthr Cartil"},{"issue":"1","key":"1566_CR19","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/j.1365-2885.2008.01035.x","volume":"32","author":"M Jung","year":"2009","unstructured":"Jung M, Lees P, Seewald W, King JN. Analytical determination and pharmacokinetics of robenacoxib in the dog. J Vet Pharmacol Ther. 2009;32(1):41\u20138.","journal-title":"J Vet Pharmacol Ther"},{"key":"1566_CR20","unstructured":"European Medicines Agency: Evaluation of the safety of veterinary medicinal products for the target animals, Directive 81\/852\/EEC. . http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/10\/WC500004360.pdf Accessed 06 Mar 2018."},{"issue":"4","key":"1566_CR21","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1111\/j.1365-2885.2008.01043.x","volume":"32","author":"ES Roberts","year":"2009","unstructured":"Roberts ES, Van Lare KA, Marable BR, Salminen WF. Safety and tolerability of 3-week and 6-month dosing of Deramaxx (deracoxib) chewable tablets in dogs. J Vet Pharmacol Ther. 2009;32(4):329\u201337.","journal-title":"J Vet Pharmacol Ther"},{"issue":"6","key":"1566_CR22","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1111\/jsap.12082","volume":"54","author":"E Grandemange","year":"2013","unstructured":"Grandemange E, Fournel S, Woehrle F. Efficacy and safety of cimicoxib in the control of perioperative pain in dogs. J Small Anim Pract. 2013;54(6):304\u201312.","journal-title":"J Small Anim Pract"},{"issue":"2","key":"1566_CR23","first-page":"127","volume":"7","author":"PD Hanson","year":"2006","unstructured":"Hanson PD, Brooks KC, Case J, Conzemius M, Gordon W, Schuessler J, et al. Efficacy and safety of firocoxib in the management of canine osteoarthritis under field conditions. Vet Ther. 2006;7(2):127\u201340.","journal-title":"Vet Ther"},{"issue":"10","key":"1566_CR24","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1292\/jvms.11-0306","volume":"74","author":"Y Kondo","year":"2012","unstructured":"Kondo Y, Takashima K, Matsumoto S, Shiba M, Otsuki T, Kinoshita G, et al. Efficacy and safety of firocoxib for the treatment of pain associated with soft tissue surgery in dogs under field conditions in Japan. J Vet Med Sci. 2012;74(10):1283\u20139.","journal-title":"J Vet Med Sci"},{"issue":"1","key":"1566_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/jvp.12185","volume":"38","author":"P Lees","year":"2015","unstructured":"Lees P, Pelligand L, Elliott J, Toutain PL, Michels G, Stegemann M. Pharmacokinetics, pharmacodynamics, toxicology and therapeutics of mavacoxib in the dog: a review. J Vet Pharmacol Ther. 2015;38(1):1\u201314.","journal-title":"J Vet Pharmacol Ther"},{"issue":"11","key":"1566_CR26","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1136\/vr.102397","volume":"176","author":"M Payne-Johnson","year":"2015","unstructured":"Payne-Johnson M, Becskei C, Chaudhry Y, Stegemann MR. Comparative efficacy and safety of mavacoxib and carprofen in the treatment of canine osteoarthritis. Vet Rec. 2015;176(11):284.","journal-title":"Vet Rec"},{"issue":"22","key":"1566_CR27","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1136\/vr.161.22.755","volume":"161","author":"K Hubbard","year":"2007","unstructured":"Hubbard K, Skelly BJ, McKelvie J, Wood JL. Risk of vomiting and diarrhoea in dogs. Vet Rec. 2007;161(22):755\u20137.","journal-title":"Vet Rec"},{"key":"1566_CR28","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/978-1-4684-4472-8_35","volume":"161","author":"DK Detweiler","year":"1983","unstructured":"Detweiler DK. Electrocardiographic monitoring in toxicological studies: principles and interpretations. Adv Exp Med Biol. 1983;161:579\u2013607.","journal-title":"Adv Exp Med Biol"},{"issue":"3","key":"1566_CR29","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2460\/ajvr.1995.56.03.275","volume":"56","author":"HM Ulloa","year":"1995","unstructured":"Ulloa HM, Houston BJ, Altrogge DM. Arrhythmia prevalence during ambulatory electrocardiographic monitoring of beagles. Am J Vet Res. 1995;56(3):275\u201381.","journal-title":"Am J Vet Res"},{"issue":"9","key":"1566_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1191\/0961203305lu2221oa","volume":"14","author":"R Caporali","year":"2005","unstructured":"Caporali R, Montecucco C. Cardiovascular effects of coxibs. Lupus. 2005;14(9):785\u20138.","journal-title":"Lupus"},{"issue":"5","key":"1566_CR31","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1097\/FJC.0b013e318157f72d","volume":"50","author":"CD Funk","year":"2007","unstructured":"Funk CD, FitzGerald GA. COX-2 inhibitors and cardiovascular risk. J Cardiovasc Pharmacol. 2007;50(5):470\u20139.","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"1566_CR32","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/clpt.2011.45","volume":"89","author":"F Salvo","year":"2011","unstructured":"Salvo F, Fourrier-Reglat A, Bazin F, Robinson P, Riera-Guardia N, Haag M, et al. Cardiovascular and gastrointestinal safety of NSAIDs: a systematic review of meta-analyses of randomized clinical trials. Clin Pharmacol Ther. 2011;89(6):855\u201366.","journal-title":"Clin Pharmacol Ther"},{"issue":"9435","key":"1566_CR33","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/S0140-6736(04)16894-3","volume":"364","author":"ME Farkouh","year":"2004","unstructured":"Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic arthritis research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364(9435):675\u201384.","journal-title":"Lancet"},{"issue":"2","key":"1566_CR34","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2174\/187152906777441803","volume":"6","author":"S Sanghi","year":"2006","unstructured":"Sanghi S, MacLaughlin EJ, Jewell CW, Chaffer S, Naus PJ, Watson LE, et al. Cyclooxygenase-2 inhibitors: a painful lesson. Cardiovasc Hematol Disord Drug Targets. 2006;6(2):85\u2013100.","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"issue":"21","key":"1566_CR35","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1056\/NEJM200011233432103","volume":"343","author":"C Bombardier","year":"2000","unstructured":"Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med. 2000;343(21):1520\u20138, 2. following 8","journal-title":"N Engl J Med"},{"issue":"1","key":"1566_CR36","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1186\/s12917-017-1269-z","volume":"13","author":"CE Toutain","year":"2017","unstructured":"Toutain CE, Heit MC, King SB, Helbig R. Safety evaluation of the interchangeable use of robenacoxib (Onsior) tablets and solution for injection in dogs. BMC Vet Res. 2017;13(1):359.","journal-title":"BMC Vet Res"},{"issue":"2","key":"1566_CR37","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1111\/j.1365-2885.2010.01227.x","volume":"34","author":"O Lecoindre","year":"2011","unstructured":"Lecoindre O, Pepin-Richard C. Tolerance of firocoxib in dogs with osteoarthritis during 90 days. J Vet Pharmacol Ther. 2011;34(2):190\u20132.","journal-title":"J Vet Pharmacol Ther"},{"issue":"2","key":"1566_CR38","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cvsm.2012.01.003","volume":"42","author":"SA Khan","year":"2012","unstructured":"Khan SA, McLean MK. Toxicology of frequently encountered nonsteroidal anti-inflammatory drugs in dogs and cats. Vet Clin North Am Small Anim Pract. 2012;42(2):289\u2013306.","journal-title":"Vet Clin North Am Small Anim Pract"}],"container-title":["BMC Veterinary Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-018-1566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12917-018-1566-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12917-018-1566-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T09:41:25Z","timestamp":1720518085000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcvetres.biomedcentral.com\/articles\/10.1186\/s12917-018-1566-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1566"],"URL":"https:\/\/doi.org\/10.1186\/s12917-018-1566-1","relation":{},"ISSN":["1746-6148"],"issn-type":[{"value":"1746-6148","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"6 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study design and the protocol was approved by the study test facility (located in the United States) Institutional Animal Care and Use Committee. The study site was fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors are employees of Elanco Animal Health, a Division of Eli Lilly and Company.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"242"}}